FUKOKU MUTUAL LIFE INSURANCE Co Cuts Stock Position in AbbVie Inc. $ABBV

FUKOKU MUTUAL LIFE INSURANCE Co lowered its position in AbbVie Inc. (NYSE:ABBV) by 0.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 244,033 shares of the company’s stock after selling 1,024 shares during the period. AbbVie makes up approximately 2.9% of FUKOKU MUTUAL LIFE INSURANCE Co’s investment portfolio, making the stock its 5th biggest holding. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in AbbVie were worth $45,297,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $25,000. TD Capital Management LLC increased its stake in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the second quarter worth $28,000. Financial Gravity Companies Inc. purchased a new stake in shares of AbbVie during the second quarter valued at $36,000. Finally, Bear Mountain Capital Inc. grew its holdings in shares of AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ABBV. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Raymond James Financial set a $256.00 price objective on AbbVie in a report on Monday, November 3rd. Finally, DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research report on Tuesday, November 4th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $240.14.

AbbVie Stock Performance

Shares of ABBV stock opened at $233.13 on Thursday. The firm has a market cap of $412.04 billion, a price-to-earnings ratio of 111.02, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company’s 50 day moving average is $226.27 and its 200 day moving average is $204.77.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the firm earned $3.00 EPS. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.